Pancreatic cancer (PCa) is characterized by its highly immunosuppressive microenvironment and resistance to immune-based therapies. Recent studies demonstrated that dendritic cells (DC) may potentiate the effect of immune checkpoint inhibitors (ICI) in many solid malignancies. In this context, tertiary lymphoid structures (TLS) represent privileged sites for presentation of tumor antigens by DCs and subsequent activation of T cell and B cell responses. In the present study we intend to reverse the immunosuppression exerted by PCa cells using tumor-lysate pulsed DCs in a neoadjuvant setting. Clarifying the interrelationship between DCs and TLSs in PCa may contribute to shed light on the mechanisms of therapy failure and to the selection of patients for novel immunotherapeutic approaches.
Here you can get further information.